Actuate Therapeutics (NASDAQ:ACTU) Coverage Initiated at HC Wainwright

Stock analysts at HC Wainwright started coverage on shares of Actuate Therapeutics (NASDAQ:ACTU) in a report released on Monday. The brokerage set a “buy” rating and a $20.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 175.86% from the stock’s current price.

Actuate Therapeutics Price Performance

Shares of NASDAQ ACTU opened at $7.25 on Monday. The business has a 50 day simple moving average of $8.18 and a 200 day simple moving average of $8.08. Actuate Therapeutics has a 52 week low of $5.51 and a 52 week high of $11.73.

Institutional Investors Weigh In On Actuate Therapeutics

Several hedge funds have recently modified their holdings of ACTU. OMERS ADMINISTRATION Corp bought a new position in Actuate Therapeutics in the fourth quarter worth $84,000. Mercer Global Advisors Inc. ADV acquired a new position in Actuate Therapeutics during the 4th quarter worth about $130,000. Voss Capital LP bought a new stake in shares of Actuate Therapeutics during the fourth quarter valued at approximately $440,000. Envestnet Asset Management Inc. bought a new position in Actuate Therapeutics in the 4th quarter valued at $83,000. Finally, BIOS Capital Management LP acquired a new stake in Actuate Therapeutics in the fourth quarter worth about $78,753,000.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.